CTOs on the Move

Zimmer Holdings, Inc.

www.zimmer.com

 
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer`s 2009 sales were approximately $4.1 billion. The Company is supported by the efforts of approximately 8,500 employees worldwide.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.zimmer.com
  • 345 East Main Street P.O. Box 708,
    Warsaw, IN USA 46580
  • Phone: 574.267.6131

Executives

Name Title Contact Details

Similar Companies

Copper Basin Medical Center

Copper Basin Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Copperhill, TN. To find more information about Copper Basin Medical Center, please visit www.copperbasin.org

Finesse

California-based Finesse Solutions brings Silicon Valley technology to bioprocessing. Better performance, integrated intelligence, and plug-and-play bioprocess flexibility are provided by Finesse SmartParts™. Our TruFluor® single-use sensors are unparalleled in the industry. Our G3 Universal™ controllers enable sophisticated cell culture or fermentation recipes to run on any size or brand of vessel. Our TruBio® software provides an easy-to-use interface for upstream bioprocessing that can harmonize old and new equipment, aggregate in-line and off-line data, and electronically facilitate global technology transfer. Finesse enables you to supercharge your R&D laboratory or scale-up to a cGMP SmartFactory with equal ease: we offer complete services, including commissioning and validation.

KCAS Bioanalytical Labs

KCAS Bioanalytical Labs is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.